Seribantumab - Merrimack Pharmaceuticals

Drug Profile

Seribantumab - Merrimack Pharmaceuticals

Alternative Names: MM-121; SAR-256212

Latest Information Update: 07 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merrimack Pharmaceuticals
  • Developer Merrimack Pharmaceuticals; Sanofi
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor modulators; ERBB-3 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Non-small cell lung cancer; Ovarian cancer
  • Phase I Gynaecological cancer; Solid tumours

Most Recent Events

  • 06 Sep 2018 Merrimack Pharmaceuticals completes enrolment in the phase II SHERLOC trial for Non-small cell lung cancer in USA, Canada, France, Germany, Hungary and Spain (NCT02387216)
  • 24 Jun 2018 Biomarkers information updated
  • 30 Oct 2017 Seribantumab receives Orphan Drug status for Non-small cell lung cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top